5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

Aug-07	Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference KNSA GlobeNewswire
Aug-06	Why This Top-Ranked IBD 50 Stock Just Tumbled On Its Earnings EXEL -7.94% Investor's Business Daily
Aug-06	Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Kimtrak Growth and Pipeline ... IMCR GuruFocus.com
Aug-06	The Race to Come Up With the Next Big Sleep Drug ALKS The Wall Street Journal
Aug-06	Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ... IMCR GuruFocus.com
Aug-06	Immunocore reports second quarter financial results and provides a business update IMCR GlobeNewswire
Aug-06	Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ... EXEL -7.94% GuruFocus.com
Aug-05	Exelixis: Q2 Earnings Snapshot EXEL Associated Press
Aug-05	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update EXEL EXEL -7.94% Business Wire
Jul-30	Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 IMCR GlobeNewswire
Jul-29	Alkermes plc Q2 2026 Earnings Call Summary ALKS Moby
Jul-28	Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call Summary KNSA +25.03% Moby
Jul-28	Alkermes PLC (ALKS) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Competitive ... ALKS GuruFocus.com
Jul-28	Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance KNSA +25.03% InvestorsHub
Jul-28	Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution KNSA +25.03% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)